This September 2017 review by Dr. Peter Scanlon on DR screening intervals. It explores the feasibility of screening certain low risk groups every 2 years instead of annually:
Screening Intervals for Diabetic Retinopathy and Implications for Care
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585285/pdf/11892_2017_Article_928.pdf
Dr. Scanlon's review is thorough and balanced and is worth a read. It is balanced in that it looks at potential cost savings as well as the potential unintended consequences of lengthening the screening interval to 2 years in low-risk patients:
Screening Intervals for Diabetic Retinopathy and Implications for Care
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585285/pdf/11892_2017_Article_928.pdf
Dr. Scanlon's review is thorough and balanced and is worth a read. It is balanced in that it looks at potential cost savings as well as the potential unintended consequences of lengthening the screening interval to 2 years in low-risk patients:
"There is an on-going concern that if patients are told that they are at the low risk of progression that:
- They may make less effort in the control of their diabetes and hence put themselves at a greater risk.
- They may be less likely to attend in the future."